Navigation Links
Treatment Adherence Emerging as Critical Theme in Improving Quality and Cost of US Healthcare
Date:4/24/2013

SUMMIT, N.J., April 24, 2013 /PRNewswire/ -- As leaders across business, policy and academia gathered at the recent World Health Care Congress (WHCC) to discuss ways to improve the quality and cost of healthcare, experts in treatment adherence identified a common theme: a patient-centric adherence strategy will be critical to achieving success.

"Healthcare reform is placing greater pressure for cost-efficiencies in the delivery of patient care and, as such, healthcare companies need to integrate treatment adherence strategies at the center of their programs," said Lina Eliasson , Ph.D., lead clinical strategist with Atlantis Healthcare, a sponsor of WHCC.  "Many exciting programs presented by industry leaders assumed a high degree of patient adherence – but in reality, treatment nonadherence is an enormous problem that can undermine the successful outcomes of any plan."

A report from the New England Healthcare Institute estimates that nonadherence to medication contributes $290 billion annually in unnecessary costs – about 13% of the total US healthcare expenditure. The report also notes that adherence rates are lower among patients with chronic conditions (i.e., diabetes, heart disease) than among those with acute conditions.

The most popular topics during the three-day WHCC conference centered on improving cost, quality and access to patient care:

  • Impact of the Patient Protection and Affordable Care Act
  • Role of integrated care and its effect on bundled care packages
  • Tele-health and implications for providers and payors
  • Employee wellness/assistance programs

While all talks referenced adherence, the topic of medication adherence was not featured as a headline item on the agenda, reinforcing the need for greater visibility.

Dr. Eliasson believes treatment adherence will emerge as an essential component in delivering positive outcomes across these areas and beyond.  "An effective strategy that motivates patients to follow prescribed treatment or a recommended health plan will decrease medication waste and overall healthcare cost, lower readmissions, and improve patient outcomes."

Understanding Intentional Nonadherence 
According to Dr. Eliasson, healthcare companies also need to have a greater awareness of the role of intentional nonadherence within the patient population. Studies show the majority of patients who don't follow their treatments are doing so on purpose – they may not believe the treatments work or that the benefits outweigh the side effects. 

"These patients need more than reminder calls and pillbox alarms," said Dr. Eliasson. "They need specific strategies and education to change their beliefs about their illness – and to motivate them to manage their health for the long term."

For more information on treatment adherence in healthcare, visit www.atlantishealthcare.com.

To learn about the World Health Care Congress, visit www.worldhealthcarecongress.com

About Atlantis Healthcare 
Established in 1993, Atlantis Healthcare creates and executes tailored patient support programs and personalized interventions to address treatment adherence across a wide range of chronic and acute diseases, worldwide.  Led by one of the world's largest health psychology teams, our patient-centric approach is designed to improve health outcomes and deliver optimal value for all healthcare stakeholders. www.atlantishealthcare.com.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.  
Lina Eliasson 
https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=112389


'/>"/>
SOURCE Atlantis Healthcare
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
(Date:6/24/2016)... , June 24, 2016  Consumers have ... and regulators/payers have placed more emphasis on patient ... patient support programs in the pharmaceutical industry have ... medications. Consequently, pharmaceutical companies are focusing on becoming ... are providing products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
Breaking Medicine News(10 mins):